Welcome to our dedicated page for Gyre Therapeutics news (Ticker: $GYRE), a resource for investors and traders seeking the latest updates and insights on Gyre Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gyre Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gyre Therapeutics's position in the market.
Gyre Therapeutics reported first-quarter 2024 financial results, with $29.8 million in cash and cash equivalents as of March 31, 2024. The company's Phase 3 clinical trial of F351 for CHB-associated liver fibrosis in the PRC is on track, with data expected by early 2025. Gyre plans to initiate a Phase 2a trial for NASH-associated liver fibrosis in the U.S. in 2025. Additionally, Gyre acquired rights to assets related to nintedanib through Gyre Pharmaceuticals to enhance competitiveness. The company's ETUARY sales reached $26.9 million in Q1 2024, showing growth from the same period in 2023. Financially, Gyre had revenues of $27.2 million for the quarter ended March 31, 2024, with net income of $9.9 million and net income attributable to common stockholders of $7.5 million. Gyre also reported adjusted net income to provide additional insights for investors.